Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Eloxx Pharmaceuticals Inc (ELOX)

Eloxx Pharmaceuticals Inc (ELOX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Eloxx Pharmaceuticals Inc 480 ARSENAL WAY WATERTOWN MA 02472 USA

www.eloxxpharma.com P: 781-577-5300

Description:

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company's lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc., formerly known as Sevion Therapeutics Inc., is based in WALTHAM, United States.

Key Statistics

Overview:

Market Capitalization, $K 2,829
Enterprise Value, $K -4,101
Shares Outstanding, K 3,143
Annual Sales, $ 0 K
Annual Net Income, $ -36,070 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -3,590 K
EBIT, $ -19,290 K
EBITDA, $ -18,050 K
60-Month Beta 2.71
% of Insider Shareholders 20.20%
% of Institutional Shareholders 2.90%
Float, K 2,508
% Float 79.80%
Short Volume Ratio 0.48

Growth:

1-Year Return -85.63%
3-Year Return -98.81%
5-Year Return -99.80%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -1.31 on 11/13/23
Latest Earnings Date 05/20/24
Earnings Per Share ttm -9.07
EPS Growth vs. Prev Qtr 33.16%
EPS Growth vs. Prev Year 63.61%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-40 on 12/02/22

ELOX Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % 0.00%
Profit Margin % 0.00%
Debt/Equity -0.27
Price/Sales N/A
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -7.29
Interest Coverage -2.37
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar